The largest study to date to look at this issue has actually found a lower rate of symptomatic intracerebral hemorrhage in patients on DOACs receiving thrombolysis than those not taking anticoagulants.
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.
Until recently, clinicians had little evidence to guide their decisions about the most effective and safe treatment for the oldest patients with atrial fibrillation and recent stroke.